SK3402000A3 - Use of a substance primary activating the osteoblastic protein kinase c/intracellular calcium pathways of a subject - Google Patents

Use of a substance primary activating the osteoblastic protein kinase c/intracellular calcium pathways of a subject Download PDF

Info

Publication number: SK3402000A3
Authority: SK; Slovakia
Prior art keywords: use according; agonist; bone; naturally occurring; prostaglandin
Prior art date: 1997-09-09

Application number

SK340-2000A

Other languages

English (en)

Slovak (sk)

Inventor

James Richard Hartke

Mark Walden Lundy

Mitchell Anthony Delong

Original Assignee

Procter & Gamble

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-09

Filing date

1998-09-04

Publication date

2000-12-11

1998-09-04 Application filed by Procter & Gamble filed Critical Procter & Gamble

2000-12-11 Publication of SK3402000A3 publication Critical patent/SK3402000A3/sk

Links

102000003923 Protein Kinase C Human genes 0.000 title claims abstract description 21
108090000315 Protein Kinase C Proteins 0.000 title claims abstract description 21
239000011575 calcium Substances 0.000 title claims abstract description 18
230000003834 intracellular effect Effects 0.000 title claims abstract description 18
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 16
229910052791 calcium Inorganic materials 0.000 title claims abstract description 16
230000003213 activating effect Effects 0.000 title abstract description 8
230000001582 osteoblastic effect Effects 0.000 title abstract description 4
230000037361 pathway Effects 0.000 title abstract 2
239000000126 substance Substances 0.000 title description 5
210000000988 bone and bone Anatomy 0.000 claims abstract description 64
239000000556 agonist Substances 0.000 claims abstract description 37
238000000034 method Methods 0.000 claims abstract description 20
208000020084 Bone disease Diseases 0.000 claims abstract description 12
150000001875 compounds Chemical class 0.000 claims description 25
230000008238 biochemical pathway Effects 0.000 claims description 21
102000000471 Prostaglandin F receptors Human genes 0.000 claims description 18
108050008995 Prostaglandin F receptors Proteins 0.000 claims description 18
150000003180 prostaglandins Chemical class 0.000 claims description 17
102000005962 receptors Human genes 0.000 claims description 15
108020003175 receptors Proteins 0.000 claims description 15
208000001132 Osteoporosis Diseases 0.000 claims description 13
210000000963 osteoblast Anatomy 0.000 claims description 13
230000002787 reinforcement Effects 0.000 claims description 12
WWSWYXNVCBLWNZ-QIZQQNKQSA-N fluprostenol Chemical group C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(C(F)(F)F)=C1 WWSWYXNVCBLWNZ-QIZQQNKQSA-N 0.000 claims description 9
229950009951 fluprostenol Drugs 0.000 claims description 9
102000015433 Prostaglandin Receptors Human genes 0.000 claims description 8
108010050183 Prostaglandin Receptors Proteins 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 8
-1 chloro-phenoxy Chemical group 0.000 claims description 7
102000017953 prostanoid receptors Human genes 0.000 claims description 6
108050007059 prostanoid receptors Proteins 0.000 claims description 6
230000002964 excitative effect Effects 0.000 claims description 5
DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 claims description 4
208000010392 Bone Fractures Diseases 0.000 claims description 4
125000003118 aryl group Chemical group 0.000 claims description 4
229910052799 carbon Inorganic materials 0.000 claims description 4
VJGGHXVGBSZVMZ-QIZQQNKQSA-N Cloprostenol Chemical group C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 claims description 3
208000010191 Osteitis Deformans Diseases 0.000 claims description 3
208000027868 Paget disease Diseases 0.000 claims description 3
229960004409 cloprostenol Drugs 0.000 claims description 3
208000027202 mammary Paget disease Diseases 0.000 claims description 3
FYBFDIIAPRHIQS-KKBLUXBBSA-N (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-thiophen-3-yloxybut-1-enyl]cyclopentyl]hept-5-enoic acid Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC=1C=CSC=1 FYBFDIIAPRHIQS-KKBLUXBBSA-N 0.000 claims description 2
239000002253 acid Substances 0.000 claims description 2
229950004900 alfaprostol Drugs 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
229950007806 delprostenate Drugs 0.000 claims description 2
125000004404 heteroalkyl group Chemical group 0.000 claims description 2
125000001072 heteroaryl group Chemical group 0.000 claims description 2
229960001160 latanoprost Drugs 0.000 claims description 2
GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 2
230000007774 longterm Effects 0.000 claims description 2
FNAMRDZHKYQEBA-YDQNNXAVSA-N methyl (2e,5z)-7-[(1r,2r,3r,5s)-2-[(e,3r)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hepta-2,5-dienoate Chemical compound COC(=O)\C=C\C\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(Cl)=C1 FNAMRDZHKYQEBA-YDQNNXAVSA-N 0.000 claims description 2
OZDSQCVLNUIYLN-JNAAKWLTSA-N methyl (z)-7-[(1r,2s,3r,5s)-2-[(3s)-5-cyclohexyl-3-hydroxypent-1-ynyl]-3,5-dihydroxycyclopentyl]hept-5-enoate Chemical compound COC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1C#C[C@@H](O)CCC1CCCCC1 OZDSQCVLNUIYLN-JNAAKWLTSA-N 0.000 claims description 2
229910052760 oxygen Inorganic materials 0.000 claims description 2
208000001685 postmenopausal osteoporosis Diseases 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
150000003536 tetrazoles Chemical class 0.000 claims description 2
229950002099 tiaprost Drugs 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
208000005368 osteomalacia Diseases 0.000 claims 1
230000004913 activation Effects 0.000 abstract description 2
230000000694 effects Effects 0.000 description 11
239000000203 mixture Substances 0.000 description 11
238000003556 assay Methods 0.000 description 10
238000011282 treatment Methods 0.000 description 9
210000004027 cell Anatomy 0.000 description 8
230000002035 prolonged effect Effects 0.000 description 8
239000003937 drug carrier Substances 0.000 description 6
101800004937 Protein C Proteins 0.000 description 5
102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 description 5
101800001700 Saposin-D Proteins 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000003883 ointment base Substances 0.000 description 4
229940094443 oxytocics prostaglandins Drugs 0.000 description 4
238000007910 systemic administration Methods 0.000 description 4
239000003826 tablet Substances 0.000 description 4
230000003442 weekly effect Effects 0.000 description 4
206010065687 Bone loss Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000001195 anabolic effect Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
230000016160 smooth muscle contraction Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
101000685323 Homo sapiens Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241000700159 Rattus Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000004097 bone metabolism Effects 0.000 description 2
230000008416 bone turnover Effects 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
239000003086 colorant Substances 0.000 description 2
230000008602 contraction Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000009499 grossing Methods 0.000 description 2
102000046038 human SDHA Human genes 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000000463 material Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
230000011164 ossification Effects 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000008439 repair process Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000018035 Dental disease Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
206010017076 Fracture Diseases 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000282339 Mustela Species 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102100024448 Prostaglandin E2 receptor EP2 subtype Human genes 0.000 description 1
235000019484 Rapeseed oil Nutrition 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000014151 Stomatognathic disease Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010046798 Uterine leiomyoma Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
239000003263 anabolic agent Substances 0.000 description 1
229940124325 anabolic agent Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000002617 bone density conservation agent Substances 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
210000002805 bone matrix Anatomy 0.000 description 1
230000010072 bone remodeling Effects 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000013170 computed tomography imaging Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
208000021863 corticosteroid-induced osteoporosis Diseases 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
229960002986 dinoprostone Drugs 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000004821 effect on bone Effects 0.000 description 1
150000002066 eicosanoids Chemical class 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000008393 encapsulating agent Substances 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
210000002149 gonad Anatomy 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
201000010260 leiomyoma Diseases 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
210000004409 osteocyte Anatomy 0.000 description 1
229940070020 other anabolic agent in atc Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
108091014625 prostaglandin binding proteins Proteins 0.000 description 1
229940127293 prostanoid Drugs 0.000 description 1
150000003814 prostanoids Chemical class 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
VILMUCRZVVVJCA-UHFFFAOYSA-M sodium glycolate Chemical compound [Na+].OCC([O-])=O VILMUCRZVVVJCA-UHFFFAOYSA-M 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960004559 theobromine Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

Health & Medical Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SK340-2000A 1997-09-09 1998-09-04 Use of a substance primary activating the osteoblastic protein kinase c/intracellular calcium pathways of a subject SK3402000A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US5821897P	1997-09-09	1997-09-09
PCT/US1998/018337 WO1999012550A1 (en)	1997-09-09	1998-09-04	Method of increasing bone volume

Publications (1)

Publication Number	Publication Date
SK3402000A3 true SK3402000A3 (en)	2000-12-11

Family

ID=22015432

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK340-2000A SK3402000A3 (en)	1997-09-09	1998-09-04	Use of a substance primary activating the osteoblastic protein kinase c/intracellular calcium pathways of a subject

Country Status (17)

Country	Link
EP (1)	EP1035853A1 (id)
JP (1)	JP2001515863A (id)
CN (1)	CN1269720A (id)
AR (1)	AR013478A1 (id)
AU (1)	AU9130298A (id)
BR (1)	BR9811775A (id)
CA (1)	CA2303799A1 (id)
CO (1)	CO5070621A1 (id)
HU (1)	HUP0003584A3 (id)
ID (1)	ID24759A (id)
IL (1)	IL134759A0 (id)
NO (1)	NO20001172L (id)
PE (1)	PE118899A1 (id)
PL (1)	PL339297A1 (id)
SK (1)	SK3402000A3 (id)
WO (1)	WO1999012550A1 (id)
ZA (1)	ZA988229B (id)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE281432T1 (de)	1999-03-05	2004-11-15	Univ Duke	C-16 ungesätigte fp-selektive prostaglandin analoge
US6894175B1 (en)	1999-08-04	2005-05-17	The Procter & Gamble Company	2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US20020172693A1 (en)	2000-03-31	2002-11-21	Delong Michell Anthony	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en)	2000-03-31	2002-03-28	Delong Mitchell Anthony	Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en)	2000-03-31	2002-01-31	Delong Mitchell Anthony	Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3607293A (en) *	1992-02-05	1993-09-03	Merck & Co., Inc.	Implant therapy for bone growth stimulation
HN1996000101A (es) *	1996-02-28	1997-06-26	Inc Pfizer	Terapia combinada para la osteoporosis

1998
- 1998-09-04 CN CN98808884A patent/CN1269720A/zh active Pending
- 1998-09-04 BR BR9811775-0A patent/BR9811775A/pt not_active Application Discontinuation
- 1998-09-04 PL PL98339297A patent/PL339297A1/xx unknown
- 1998-09-04 EP EP98943532A patent/EP1035853A1/en not_active Withdrawn
- 1998-09-04 SK SK340-2000A patent/SK3402000A3/sk unknown
- 1998-09-04 IL IL13475998A patent/IL134759A0/xx unknown
- 1998-09-04 HU HU0003584A patent/HUP0003584A3/hu unknown
- 1998-09-04 WO PCT/US1998/018337 patent/WO1999012550A1/en not_active Ceased
- 1998-09-04 JP JP2000510447A patent/JP2001515863A/ja not_active Withdrawn
- 1998-09-04 AU AU91302/98A patent/AU9130298A/en not_active Abandoned
- 1998-09-04 CA CA002303799A patent/CA2303799A1/en not_active Abandoned
- 1998-09-04 ID IDW20000638A patent/ID24759A/id unknown
- 1998-09-08 AR ARP980104480A patent/AR013478A1/es not_active Application Discontinuation
- 1998-09-09 ZA ZA988229A patent/ZA988229B/xx unknown
- 1998-09-09 CO CO98051809A patent/CO5070621A1/es unknown
- 1998-09-09 PE PE1998000855A patent/PE118899A1/es not_active Application Discontinuation
2000
- 2000-03-07 NO NO20001172A patent/NO20001172L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AR013478A1 (es)	2000-12-27
WO1999012550A1 (en)	1999-03-18
ID24759A (id)	2000-08-03
NO20001172L (no)	2000-05-08
ZA988229B (en)	1999-03-09
PL339297A1 (en)	2000-12-04
CN1269720A (zh)	2000-10-11
NO20001172D0 (no)	2000-03-07
CA2303799A1 (en)	1999-03-18
EP1035853A1 (en)	2000-09-20
BR9811775A (pt)	2000-08-29
HUP0003584A3 (en)	2002-12-28
IL134759A0 (en)	2001-04-30
HUP0003584A2 (hu)	2001-02-28
AU9130298A (en)	1999-03-29
PE118899A1 (es)	2000-02-03
JP2001515863A (ja)	2001-09-25
CO5070621A1 (es)	2001-08-28

Publication	Publication Date	Title
AU739275B2 (en)	2001-10-11	Method of increasing bone volume using non-naturally-occurring FP selective agonists
JP4846063B2 (ja)	2011-12-28	選択的ｓ１ｐ１レセプターアゴニストの投与法
Alm	1998	Prostaglandin derivates as ocular hypotensive agents
RU2478384C2 (ru)	2013-04-10	Курс лечения с использованием агониста рецептора s1p
JP2021042248A (ja)	2021-03-18	Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療
FR2774591A1 (fr)	1999-08-13	Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
TW200808324A (en)	2008-02-16	Method for shortening hospital stay in patients with congestive heart failure and acute fluid overload
US20040171582A1 (en)	2004-09-02	Pancreatic juice secretion regulators comprising lpa receptor controller
US20070142266A1 (en)	2007-06-21	Combination comprising a P-gp inhibitor and an anti-epileptic drug
SK3402000A3 (en)	2000-12-11	Use of a substance primary activating the osteoblastic protein kinase c/intracellular calcium pathways of a subject
US7238718B2 (en)	2007-07-03	Method for treating myolytic disease and method for screening antimyolytic agent
EP1158969A2 (en)	2001-12-05	Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume
CN101217960B (zh)	2010-12-15	用于改善尿毒症的治疗药和处置方法
CZ2000808A3 (cs)	2000-06-14	Použití selektivního FP agonisty, který se přirozeně nevyskytuje
WO2000051616A1 (en)	2000-09-08	Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
MXPA00002395A (en)	2001-12-04	Method of increasing bone volume
JP2002538122A (ja)	2002-11-12	天然に存在しないｆｐ選択的アゴニストおよび骨吸収抑制化合物を用いる骨体積の増加方法
CZ20014406A3 (cs)	2002-04-17	Farmaceutický prostředek
HUE033403T2 (en)	2017-11-28	Combination with (3S, 3S ') - 4,4'-disulfandyl-bis (3-aminobutane-1-sulfonic acid) and a second antihypertensive agent
MXPA00002394A (en)	2001-12-13	Method of increasing bone volume using non-naturally-occurring fp selective agonists
EA006202B1 (ru)	2005-10-27	Способ подавления образования спаек у млекопитающего